Remifentanil deal builds Paion's anaesthesia prospects
This article was originally published in Scrip
Executive Summary
The German firm Paion has signed a deal for the German distribution rights of the generic anaesthesia product remifentanil. It says the ultra short-acting opioid is an ideal companion product for the anaesthesia/sedative drug candidate remimazolam, on which it decided earlier this year to focus in a strategic realignment around anaesthesia and critical care (scripintelligence.com, 29 February 2012).